1
|
Ntafoulis I, Koolen SLW, den Hollander CWJ, Ju J, Kers T, van den Bosch TPP, Panth K, Mezzanotte L, Mustafa DAM, Stubbs AP, Dirven CMF, Leenstra S, Lamfers MLM. EXTH-15. DRUG SCREENING ON PATIENT GBM CELL CULTURES IDENTIFIES OMACETAXINE MEPESUCCINATE AS A POTENT ANTI-GLIOMA AGENT WITH THE ABILITY TO CROSS THE BLOOD-BRAIN-BARRIER. Neuro Oncol 2022. [PMCID: PMC9660925 DOI: 10.1093/neuonc/noac209.814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
INTRODUCTION
Little progress has been made in the development of effective new therapies for glioblastoma (GBM) the past decades. Fresh patient-derived GBM cell culture models have become the gold standard for GBM drug discovery and development. One of the major obstacles in identifying novel candidate drugs against GBM remains the blood-brain barrier (BBB). Therefore, it is crucial to select drugs with favourable physicochemical properties to cross BBB and reach the tumour tissue in therapeutically effective concentrations. In current drug repurposing approach, we evaluated available anti-cancer agents in our patient-derived drug screening platform against GBM.
METHODS
The FDA-approved Oncology Drug Set II library was tested on 45 primary GBM cell cultures. We developed a drug shortlisting pipeline combining efficacy data with pharmacodynamic and pharmacokinetic characteristics of each compound. The therapeutic efficacy of the selected agent was assessed in an orthotopic mouse PDX model, while penetration into the CNS by LC/MS/MS.
RESULTS
Omacetaxine mepesuccinate (OMA) was ranked as one of the most promising candidates applying our drug selection approach. In vitro, OMA revealed anti-tumour activity at IC50 values well-below reported Cmax plasma values in approximately 80% of GBM cultures. NanoString nCounter analysis, revealed DNA damage repair as the main pathway involved in OMA’s anti-tumour effect. Activation of caspase 3/7 activity and decrease of glioma cell invasiveness were also linked to its anti-tumour effect. In vivo, 1mg/kg dose of OMA was found to reach the brain tumour tissue in concentrations similar to the reported IC50 values in vitro. No adverse reactions were noted and a survival benefit was observed in a proportion of the treated mice.
CONCLUSIONS
At 1 mg/kg, OMA reaches the tumour brain tissue in therapeutically effective concentrations in mice while a moderate therapeutic benefit was observed. Additional in vivo experiments are ongoing investigating higher dosages of OMA and longer exposure.
Collapse
Affiliation(s)
- Ioannis Ntafoulis
- Dept of Neurosurgery, Erasmus Medical Center , Rotterdam , Netherlands
| | - Stijn L W Koolen
- Dept of Medical Oncology, Erasmus Medical Center , Rotterdam , Netherlands
| | | | - Jie Ju
- Department of Pathology and Clinical Bioinformatics, Erasmus Medical Center , Rotterdam , Netherlands
| | - Trisha Kers
- Dept of Neurosurgery, Erasmus MC , Rotterdam , Netherlands
| | | | - Kranthi Panth
- Department of Molecular Genetics, Erasmus MC , Rotterdam , Netherlands
| | - Laura Mezzanotte
- Department of Molecular Genetics, Erasmus MC , Rotterdam , Netherlands
| | | | - Andrew P Stubbs
- Dept of Pathology and Clinical Bioinformatics, Erasmus Medical Center , Rotterdam , Netherlands
| | | | - Sieger Leenstra
- Dept of Neurosurgery,Erasmus Medical Center , Rotterdam , Netherlands
| | | |
Collapse
|
2
|
Peeters S, Panth K, Lieuwes N, Bussink J, Van Dongen G, Dubois L, Lambin P. PO-0785: 89Zr-Cetuximab uptake in primary head and neck xenografts is independent of the expression of EGFR and perfusion. Radiother Oncol 2014. [DOI: 10.1016/s0167-8140(15)30903-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|